Movement Alert｜Genscript Biotech Falls 5.18% in Regular Trading, CARVYKTI Q2 Sales Growth Deceleration Extends Profit-Taking Pressure

Market Focus10:23

On July 17, Genscript Biotech fell 5.18% in regular trading, trading at HKD 13.62/share, with turnover of HKD 81.64 million.

On the news front, the company's associate Legend Biotech disclosed that CARVYKTI generated net trade sales of approximately $657 million for the quarter ended June 30, representing roughly 10% sequential growth from Q1's $597 million. This marks a notable deceleration from the 62% year-over-year growth recorded in Q1. Genscript had previously rallied over 5% on both July 13 and July 15, driven by CXO sector mid-year earnings catalysts, accumulating significant gains. Following the sales data release, profit-taking pressure emerged on July 16 and has continued into today's session.

The broader Life Sciences Tools & Services sector is under broad-based selling pressure, with WuXi AppTec down 5.37%, WuXi Biologics down 4.58%, Insilico down 10.4%, WuXi XDC down 7.34%, and JOINN down 9.61%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1164749324?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-17 10:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1164749324","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Genscript Biotech Falls 5.18% in Regular Trading, CARVYKTI Q2 Sales Growth Deceleration Extends Profit-Taking Pressure","media":"Market Focus","content":"<p><p>On July 17, Genscript Biotech fell 5.18% in regular trading, trading at HKD 13.62/share, with turnover of HKD 81.64 million.</p><p>On the news front, the company's associate Legend Biotech disclosed that CARVYKTI generated net trade sales of approximately $657 million for the quarter ended June 30, representing roughly 10% sequential growth from Q1's $597 million. This marks a notable deceleration from the 62% year-over-year growth recorded in Q1. Genscript had previously rallied over 5% on both July 13 and July 15, driven by CXO sector mid-year earnings catalysts, accumulating significant gains. Following the sales data release, profit-taking pressure emerged on July 16 and has continued into today's session.</p><p>The broader Life Sciences Tools &amp; Services sector is under broad-based selling pressure, with WuXi AppTec down 5.37%, WuXi Biologics down 4.58%, Insilico down 10.4%, WuXi XDC down 7.34%, and JOINN down 9.61%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Genscript Biotech Falls 5.18% in Regular Trading, CARVYKTI Q2 Sales Growth Deceleration Extends Profit-Taking Pressure</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Genscript Biotech Falls 5.18% in Regular Trading, CARVYKTI Q2 Sales Growth Deceleration Extends Profit-Taking Pressure\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-17 10:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 17, Genscript Biotech fell 5.18% in regular trading, trading at HKD 13.62/share, with turnover of HKD 81.64 million.</p><p>On the news front, the company's associate Legend Biotech disclosed that CARVYKTI generated net trade sales of approximately $657 million for the quarter ended June 30, representing roughly 10% sequential growth from Q1's $597 million. This marks a notable deceleration from the 62% year-over-year growth recorded in Q1. Genscript had previously rallied over 5% on both July 13 and July 15, driven by CXO sector mid-year earnings catalysts, accumulating significant gains. Following the sales data release, profit-taking pressure emerged on July 16 and has continued into today's session.</p><p>The broader Life Sciences Tools &amp; Services sector is under broad-based selling pressure, with WuXi AppTec down 5.37%, WuXi Biologics down 4.58%, Insilico down 10.4%, WuXi XDC down 7.34%, and JOINN down 9.61%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01548","symbol_name":"金斯瑞生物科技","start_time":0,"source_url":"","article_id":"1164749324","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1164749324","pubTimestamp":1784255017,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 17, Genscript Biotech fell 5.18% in regular trading, trading at HKD 13.62/share, with turnover of HKD 81.64 million.On the news front, the company's associate Legend Biotech disclosed that...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01548":"金斯瑞生物科技"},"translate_title":"走势提醒|金斯瑞生物常规交易下跌5.18%，CARVYKTI Q2销售增长放缓扩大获利回吐压力","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01548":1},"content_text":"On July 17, Genscript Biotech fell 5.18% in regular trading, trading at HKD 13.62/share, with turnover of HKD 81.64 million.On the news front, the company's associate Legend Biotech disclosed that CARVYKTI generated net trade sales of approximately $657 million for the quarter ended June 30, representing roughly 10% sequential growth from Q1's $597 million. This marks a notable deceleration from the 62% year-over-year growth recorded in Q1. Genscript had previously rallied over 5% on both July 13 and July 15, driven by CXO sector mid-year earnings catalysts, accumulating significant gains. Following the sales data release, profit-taking pressure emerged on July 16 and has continued into today's session.The broader Life Sciences Tools & Services sector is under broad-based selling pressure, with WuXi AppTec down 5.37%, WuXi Biologics down 4.58%, Insilico down 10.4%, WuXi XDC down 7.34%, and JOINN down 9.61%.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1164749324","isCrawlerRequest":true}